Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma

Journal of Glaucoma

Volumn 23, Issue 8, 2014, Pages 535-540

  Riva, Ivano ^a   Katsanos, Andreas ^b   Floriani, Irene ^a   Biagioli, Elena ^c   Konstas, Anastasios G P ^d   Centofanti, Marco ^e   Quaranta, Luciano ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF IOANNINA   (Greece)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d AHEPA UNIVERSITY HOSPITAL   (Greece)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Circadian intraocular pressure; Open angle glaucoma; Prostaglandin analogue; Travoprost

Indexed keywords

BENZALKONIUM CHLORIDE; EYE DROPS; TRAVOPROST; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS HYPERCHROMIA; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; OPEN STUDY; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TOPICAL TREATMENT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES;

EID: 84916605892     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0000000000000073     Document Type: Article

References (44)

1. StewartWC, Konstas AG, Nelson LA, et al. Meta-Analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115: 1117-1122, e1111.
2. Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114: 653-657.
3. Yan DB, Battista RA, Haidich AB, et al. Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with openangle glaucoma. Curr Med Res Opin. 2008;24: 3023-3027.
4. Quaranta L, Katsanos A, Russo A, et al. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013;58: 26-41.
5. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: A meta-Analysis of randomized controlled clinical trials. J Glaucoma. 2008;17: 667-673.
6. Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-Angle glaucoma: A systematic review and metaanalysis. J Ocul Pharmacol Ther. 2013;29: 382-389.
7. Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6: 45-52.
8. Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002;18: 313-324.
9. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003;44: 715-721.
10. Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-Timolol fixed combinations in primary open-Angle glaucoma. Curr Med Res Opin. 2011;27: 1949-1958.
11. Konstas AG, Mikropoulos D, Haidich AB, et al. Twenty-fourhour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-Angle glaucoma. Br J Ophthalmol. 2009;93: 481-485.
12. Konstas AG, Mikropoulos D, Kaltsos K, et al. 24-hour intraocular pressure control obtained with evening-versus morning-dosed travoprost in primary open-Angle glaucoma. Ophthalmology. 2006;113: 446-450.
13. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113: 239-246.
14. Przydryga JT, Egloff C. Intraocular pressure lowering efficacy of travoprost. Eur J Ophthalmol. 2004;14: 416-422.
15. Franks WA, Renard JP, Cunliffe IA, et al. A 6-week, doublemasked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0: 005%/timolol 0.5% in patients with primary open-Angle glaucoma or ocular hypertension. Clin Ther. 2006;28: 332-339.
16. Kumar RS, Istiantoro VW, Hoh ST, et al. Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma. J Glaucoma. 2007;16: 606-609.
17. Konstas AG, Mikropoulos DG, Irkec M. Open-Angle glaucoma and ocular perfusion. Br J Ophthalmol. 2010;94: 1273-1274.
18. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: A retrospective review. J Glaucoma. 2003;12: 232-236.
19. Barkana Y, Anis S, Liebmann J, et al. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol. 2006;124: 793-797.
20. Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-Angle glaucoma. J Glaucoma. 2008;17: 36-39.
21. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-Angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122: 532-538.
22. Leske MC, Wu SY, Honkanen R, et al. Nine-year incidence of open-Angle glaucoma in the Barbados Eye Studies. Ophthalmology. 2007;114: 1058-1064.
23. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-Angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132: 472-484.
24. Alm A, Widengard I. Latanoprost: Experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 2000;78: 71-76.
25. Costagliola C, Del Prete A, VerolinoM, et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: A 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol. 2002;240: 379-386.
26. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105: 82-87.
27. Kashiwagi K, Tsumura T, Tsukahara S. Long-Term effects of latanoprost monotherapy on intraocular pressure in Japanese glaucoma patients. J Glaucoma. 2008;17: 662-666.
28. Fristrom B, Uusitalo H. A randomized, 36-month, postmarketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Acta Ophthalmol. 2010;88: 37-43.
29. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47(suppl 1): S65-S76.
30. Nilsson SF, Drecoll E, Lutjen-Drecoll E, et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 2006; 47: 4042-4049.
31. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38: 2772-2780.
32. Weinreb RN, Toris CB, Gabelt BT, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002;47(suppl 1): S53-S64.
33. Boger WP III. Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28(suppl): 235-242.
34. Gandolfi SA. Restoring sensitivity to timolol after long-Term drift in primary open-Angle glaucoma. Invest Ophthalmol Vis Sci. 1990;31: 354-358.
35. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47: 2917-2923.
36. Quaranta L, Miglior S, Floriani I, et al. Effects of the timololdorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. Invest Ophthalmol Vis Sci. 2008;49: 4226-4231.
37. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122: 957-965.
38. The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130: 429-440.
39. Stewart WC, Day DG, Jenkins JN, et al. Mean intraocular pressure and progression based on corneal thickness in primary open-Angle glaucoma. J Ocul Pharmacol Ther. 2006; 22: 26-33.
40. Hollo G, Quaranta L, Cvenkel B, et al. Risk factors associated with progression in exfoliative glaucoma patients. Ophthalmic Res. 2012;47: 208-213.
41. Seong GJ, Rho SH, Kim CS, et al. Potential benefit of intraocular pressure reduction in normal-Tension glaucoma in South Korea. J Ocul Pharmacol Ther. 2009;25: 91-96.
42. Jonas JB, Budde WM, Stroux A, et al. Diurnal intraocular pressure profiles and progression of chronic open-Angle glaucoma. Eye (Lond). 2007;21: 948-951.
43. Stewart WC, Kolker AE, Sharpe ED, et al. Long-Term progression at individual mean intraocular pressure levels in primary open-Angle and exfoliative glaucoma. Eur J Ophthalmol. 2008;18: 765-770.
44. Konstas AG, Quaranta L, Mikropoulos DG, et al. Peak intraocular pressure and glaucomatous progression in primary open-Angle glaucoma. J Ocul Pharmacol Ther. 2012; 28: 26-32.